Differentiated thyroid cancer – possible risks of treatment, suppressive therapy and adherence to current recommendations
Authors:
Petra Němčíková 1,2; Ludmila Brunerová 1,3
Authors‘ workplace:
3. lékařská fakulta Univerzity Karlovy, Praha
1; Oddělení nukleární medicíny Nemocnice České Budějovice
2; Interní klinika FNKV a 3. LF UK Praha
3
Published in:
Vnitř Lék 2023; 69(5): 312-315
Category:
doi:
https://doi.org/10.36290/vnl.2023.061
Overview
Thyroid carcinoma (TC) is rare and represents 1–2 % of all human tumors. The incidence of TC has been increasing worldwide. TC comprises of a heterogeneous group of tumours with variable biological activity. Women are mostly affected. TC can be divided in differentiated TC/DTCs (papillary – PTC, follicular – FTC, from Hürthle cells – HCC), medullary carcinoma – MTC and anaplastic thyroid cancer – ATC. In this article, we focus on possible pitfalls of suppression therapy (cardiovascular, bone and mental), particularly in low-risk patients, and we discuss the data on the adherence to guidelines for suppression therapy in DTC.
Keywords:
adherence – risks – differentiated thyroid cancer – supression therapy
Sources
- Epidemiologie zhoubných nádorů data z roku 2021. Available from: www: <https:// www.svod.cz/>.
- Ahn HS, Kim HJ, Kim KH, et al. Thyroid cancer screening in South Korea increases detection of papillary cancers with no impact on other subtypes or thyroid cancer mortality. Thyroid. 2016;26(11):1535-1540.
- Fagin JA, Wells SA. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016;375(11):1054-1067.
- Vlček P, Nováková D, Katra R. Karcinomy štítné žlázy: současný pohled na diagnostiku a léčbu. Vnitr Lek. 2017;63(9):572-579.
- Brierley JD (ed.), Gospodarowicz MK (ed.), Wittekind Ch (ed). TNM Classification of Malignant Tumours, 8th Edition. Wiley-Blackwell 2016. ISBN 978-1-119-26357-9. Available from: <https://www.wiley.com/en-gb/TNM+Classification+of+Malignant+Tumours%2C+8th+ Edition-p-9781119263579>.
- Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1-133.
- Haddad R.I. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Thyroid Carcinoma. NCCN; Plymouth, PA, USA 2023. Available from: <https://www.nccn.org/pro- fessionals/physician_gls/pdf/thyroid.pdf>
- Bernardi S, Palermo A, Grasso RF, et al. Current Status and Challenges of US-Guided Radiofrequency Ablation of Thyroid Nodules in the Long Term: A Systematic Review. Cancers (Basel) 2021;13(11):2746.
- Avram AM, Giovanella L, Greenspan B, et al. SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version. J Nucl Med. 2022,63(6):15N-35N.
- Sawin CT, Geller A, Wolf P, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrilation in older persons. N Engl J Med. 1994;331(19):1249-1952.
- Ochs N, Auer R, Bauer DC et al. Metaanalysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med. 2008;148(11):832-845. 12.
- Quan ML, Pasieka JL, Rorstad O. Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: A systematic overview of the literature. J Surg Oncol. 2002;79(1):62-70.
- Ran B, Wei F, Gong J, Xu H, et al. Application and prospect of trabecular bone score in differentiated thyroid cancer patients receiving thyrotropin suppression therapy. Front Endocrinol (Lausanne). 2022 Oct 12;13:1004962. doi: 10.3389/fendo.2022.1004962
- Ku EJ, Yoo WS, Lee EK, et al. Effect of TSH Suppression Therapy on Bone Mineral Density in Differentiated Thyroid Cancer: A Systematic Review and Meta-analysis. J Clin Endocrinol Metab. 2021;106(12):3655-3667.
- Park H, Park J, Yoo H, et al. Bone-density testing interval and transition to osteoporosis in differentiated thyroid carcinoma patients on TSH suppression therapy. Clin Endocrinol (Oxf) 2022;97(1):130-136.
- Gülsoy Kirnap N, Turhan Iyidir Ö, Bozkuş Y, et al. The effect of iatrogenic subclinical hyperthyroidism on anxiety, depression and quality of life in differentiated thyroid carcinoma. Turk J Med Sci. 2020;50(4):870-876.
- Altuntaş SÇ, Hocaoğlu Ç. Effects of Chronic Suppression or Oversuppression of Thyroid-Stimulating Hormone on Psychological Symptoms and Sleep Quality in Patients with Differentiated Thyroid Cancer. Horm Metab Res. 2021;53(10):683-691.
- Papaleontiou M, Chen DW, Banerjee M. et al. Thyrotropin Suppression for Papillary Thyroid Cancer: A Physician Survey Study. Thyroid. 2021;31(9):1383-1390.
- Yavuz DG, Yazan CD, Hekimsoy Z, et al. Assesment of attainment of recommended TSH levels and levothyroxine compliance in differentiated thyroid cancer patients. Clin Endocrinol (Oxf) 2022;97(6):833-840.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2023 Issue 5
Most read in this issue
- Acute kidney injury in patients with cirrhosis – practical summary
- Dyslipidemia – the known unknown
- News in respiratory medicine
- Cardiovascular disease and kidney transplantation